ANAB
$67.29
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Intraday
Recent News
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga outlined progress on the company’s planned separation into two entities, provided an update on its royalty streams and ongoing litigation related to GSK’s Jemperli, and discussed the clinical and commercial rationale for the biopharma assets that will be spun
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible
AnaptysBio (NASDAQ:ANAB) is preparing to separate its business into two entities, with CEO Daniel Faga telling Barclays Senior Biotech Analyst Gena Wang that the company expects to create a new company, First Tracks Biotherapeutics, within “a month or two.” Under the plan, the existing AnaptysBio na
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress
AnaptysBio (ANAB) has drawn fresh attention after reporting a profitable fourth quarter and a sharply smaller full year loss, helped by collaboration revenues, milestone payments, and higher royalties tied to GSK’s cancer drug Jemperli. See our latest analysis for AnaptysBio. The stock’s sharp 1 year total shareholder return of about 2.5x, together with a 90 day share price return of 29.15% and 27.43% year to date, suggests momentum has been building around the recent earnings turnaround,...
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference
AnaptysBio (NASDAQ:ANAB) outlined plans at TD Cowen’s 46th Annual Healthcare Conference to separate its operations into two publicly traded companies, with executives framing the move as a way to unlock the value of a growing royalty stream while allowing the remaining biopharma business to focus on